José Cidade

Dr. José Cidade

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 December 2021 in ERJ Open Research
Verified
Journal Article
Open access
PDF file
LRLuis F Reyes
Luis F Reyes
SMSrinivas Murthy
Srinivas Murthy
EGEsteban Garcia-Gallo
Esteban Garcia-Gallo
MIMike Irvine
Mike Irvine
LMLaura Merson
Laura Merson
POPiero L. Olliaro
Piero L. Olliaro
Due to the large number of patients with severe coronavirus disease 2019 (COVID-19), many were treated outside the traditional walls of the intensive care unit (ICU), and in many cases, by personnel who were not trained in critical care. The clinical characteristics and the relative impact of caring for severe COVID-19 patients outside the ICU is unknown. This was a multinational, multicentre, prospective cohort study embedded in the International Severe Acute Respiratory and Emerging Infection Consortium World Health Organization COVID-19 platform. Severe COVID-19 patients were identified as those admitted to an ICU and/or those treated with one of the following treatments: invasive or noninvasive mechanical ventilation, high-flow nasal cannula, inotropes or vasopressors. A logistic generalised additive model was used to compare clinical outcomes among patients admitted or not to the ICU. A total of 40 440 patients from 43 countries and six continents were included in this analysis. Severe COVID-19 patients were frequently male (62.9%), older adults (median (interquartile range (IQR), 67 (55–78) years), and with at least one comorbidity (63.2%). The overall median (IQR) length of hospital stay was 10 (5–19) days and was longer in patients admitted to an ICU than in those who were cared for outside the ICU (12 (6–23) daysversus8 (4–15) days, p<0.0001). The 28-day fatality ratio was lower in ICU-admitted patients (30.7% (5797 out of 18 831)versus39.0% (7532 out of 19 295), p<0.0001). Patients admitted to an ICU had a significantly lower probability of death than those who were not (adjusted OR 0.70, 95% CI 0.65–0.75; p<0.0001). Patients with severe COVID-19 admitted to an ICU had significantly lower 28-day fatality ratio than those cared for outside an ICU.

1 November 2015 in GE - Portuguese Journal of Gastroenterology
Verified
Journal Article
Open access
JCJosé Cidade
José Cidade
MCMarta Borges Canha
Marta Borges Canha
ALAdelino Ferreira Leite-Moreira
Adelino Ferreira Leite-Moreira
PPPedro Pimentel-Nunes
Pedro Pimentel-Nunes
Metabolic syndrome is an emerging problem in developed countries and presents itself as a potential threat worldwide. The role of diabetes, dyslipidaemia and hepatic steatosis as pivotal components of the metabolic syndrome is well known. However, their common persistent chronic inflammation and its potential cause still elude. This systematic review aims to present evidence of the mechanisms that link the intestinal microbioma, innate immunity and metabolic syndrome. A comprehensive research was made using PubMed database and 35 articles were selected. We found that metabolic syndrome is associated to increased levels of innate immunity receptors, namely, Toll-like receptors, both in intestine and systemically and its polymorphisms may change the risk of metabolic syndrome development. Microbioma dysbiosis is also present in metabolic syndrome, with lower prevalence of Bacteroidetes and increased prevalence of Firmicutes populations. The data suggest that the link between intestinal microbiota and Toll-like receptors can negatively endanger the metabolic homeostasis. Current evidence suggests that innate immunity and intestinal microbiota may be the hidden link in the metabolic syndrome development mechanisms. In the near future, this can be the key in the development of new prophylactic and therapeutic strategies to treat metabolic syndrome patients.

1 January 2022 in Clinical and Applied Thrombosis/Hemostasis
Verified
Journal Article
Open access
JCJosé Cidade
José Cidade
LCLuís Coelho
Luís Coelho
VCVasco Costa
Vasco Costa
RMRui Morais
Rui Morais
PMPatrícia Moniz
Patrícia Moniz
PPPedro Póvoa
Pedro Póvoa
Background: COVID-19 is a new form of acute respiratory failure leading to multiorgan failure and ICU admission. Gathered evidence suggests that a 3-fold rise in D-dimer concentrations may be linked to poor prognosis and higher mortality. Purpose: To describe D-dimer admission profile in severe ICU COVID19 patients and its predictive role in outcomes and mortality. Methods: Single-center retrospective cohort study. All adult patients admitted to ICU with COVID19 were divided into 3 groups: (1) Lower-values group (D-dimer levels < 3-fold normal range value [NRV] [500ng/mL]), Intermediate-values group (D-dimer ≥3-fold and <10-fold NRV) and Higher-value group (≥10-fold NRV). Results: 118 patients (mean age 63 years, 73% males) were included (N = 73 Lower-values group, N = 31 Intermediate-values group; N = 11 Higher-values group). Mortality was not different between groups (p = 0.51). Kaplan-Meier survival curves revealed no differences (p = 0.52) between groups, nor it was verified even when gender, age, ICU length of stay, and SOFA score were considered as covariables. Conclusions: In severe COVID19 patients, the D-dimer profile does not retain a predictive value regarding patients’ survivability and should not be used as a surrogate of disease severity.

2 January 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
VCVasco Salgado Costa
Vasco Salgado Costa
JCJosé Cidade
José Cidade
IMInês Miguel de Noronha Medeiros
Inês Miguel de Noronha Medeiros
PPPedro Póvoa
Pedro Póvoa
The prompt identification and correction of patient–ventilator asynchronies (PVA) remain a cornerstone for ensuring the quality of respiratory failure treatment and the prevention of further injury to critically ill patients. These disruptions, whether due to over- or under-assistance, have a profound clinical impact not only on the respiratory mechanics and the mortality associated with mechanical ventilation but also on the patient’s cardiac output and hemodynamic profile. Strong evidence has demonstrated that these frequently occurring and often underdiagnosed events have significant prognostic value for mechanical ventilation outcomes and are strongly associated with prolonged ICU stays and hospital mortality. Halting the consequences of PVA relies on the correct identification and approach of its underlying causes. However, this often requires advanced knowledge of respiratory physiology and the evaluation of complex ventilator waveforms in patient–ventilator interactions, posing a challenge to intensive care practitioners, in particular, those less experienced. This review aims to outline the most frequent types of PVA and propose a clinical algorithm to provide physicians with a structured approach to assess, accurately diagnose, and correct PVA.

9 July 2022 in World Journal of Critical Care Medicine
Verified
Journal Article
Open access
JCJosé Cidade
José Cidade
LCLm Coelho
Lm Coelho
VCVasco Costa
Vasco Costa
RMRui Morais
Rui Morais
PMPatrícia Moniz
Patrícia Moniz
PPPedro Povoa
Pedro Povoa
Septic shock 3.0 criteria application in severe COVID-19 patients: An unattended sepsis population with high mortality risk

22 September 2023 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
JCJosé Cidade
José Cidade
LCLuis Coelho
Luis Coelho
PPPedro Póvoa
Pedro Póvoa
The SARS-CoV-2 infection is a cause of hypoxemic acute respiratory failure, leading to frequent intensive care unit (ICU) admission. Due to invasive organ support and immunosuppressive therapies, these patients are prone to nosocomial infections. Our aim was to assess the value of daily measurements of C-reactive protein (CRP) and Procalcitonin (PCT) in the early identification of ICU-acquired infections in COVID-19 patients. Methods: We undertook a prospective observational cohort study (12 months). All adult mechanically ventilated patients admitted for ≥72 h to ICU with COVID-19 pneumonia were divided into an infected group (n = 35) and a non-infected group (n = 83). Day 0 was considered as the day of the diagnosis of infection (infected group) and Day 10 was that of ICU stay (non-infected group). The kinetics of CRP and PCT were assessed from Day –10 to Day 10 and evaluated using a general linear model, univariate, repeated-measures analysis. Results: 118 patients (mean age 63 years, 74% males) were eligible for the analysis. The groups did not differ in patient age, gender, CRP and PCT serum levels at ICU admission. However, the infected group encompassed patients with a higher severity (SOFA score at ICU admission, p = 0.009) and a higher 28–day mortality (p < 0.001). Before D0, CRP kinetics showed a significant increase in infected patients, whereas in noninfected it remained almost unchanged (p < 0.001), while PCT kinetics did not appear to retain diagnostic value to predict superinfection in COVID-19 patients (p = 0.593). Conclusion: COVID-19 patients who developed ICU-acquired infections exhibited different biomarker kinetics before the diagnosis of those infections. Daily CRP monitoring and the recognition of the CRP kinetics could be useful in the prediction of ICU-acquired infections.